Daily Respiratory Research Analysis
Three studies reshape respiratory medicine from different angles: (1) a mechanistic JCI study shows melanocortin-4 receptor (MC4R) agonism abolishes sleep apneas in obese mice via parafacial MC4R+ neurons, illuminating a neural target for sleep-disordered breathing; (2) a large real-world cohort suggests GLP-1 receptor agonists reduce COPD exacerbations, pneumonia, oxygen dependence, and mortality in patients on single-inhaler triple therapy; (3) a meta-analysis finds GLP-1 agonists increase res
Summary
Three studies reshape respiratory medicine from different angles: (1) a mechanistic JCI study shows melanocortin-4 receptor (MC4R) agonism abolishes sleep apneas in obese mice via parafacial MC4R+ neurons, illuminating a neural target for sleep-disordered breathing; (2) a large real-world cohort suggests GLP-1 receptor agonists reduce COPD exacerbations, pneumonia, oxygen dependence, and mortality in patients on single-inhaler triple therapy; (3) a meta-analysis finds GLP-1 agonists increase residual gastric contents without increasing peri-operative pulmonary aspiration, guiding anesthesia practice.
Research Themes
- Neural control of breathing and novel targets for sleep-disordered breathing
- Metabolic therapies intersecting with COPD outcomes
- Perioperative management in patients on GLP-1 receptor agonists
Selected Articles
1. Targeting melanocortin 4 receptor to treat sleep-disordered breathing in mice.
In obese mice, the MC4R agonist setmelanotide increased minute ventilation, enhanced the hypercapnic ventilatory response, and abolished sleep apneas. Mechanistically, parafacial MC4R+ neurons (but not NTS MC4R+ neurons) mediated these effects; their chemogenetic activation augmented HCVR, and their ablation eliminated setmelanotide’s impact.
Impact: This work identifies a discrete brainstem neural population as a druggable node for SDB and provides preclinical proof that MC4R agonism can normalize breathing during sleep.
Clinical Implications: MC4R agonists (e.g., setmelanotide) could be repurposed to treat sleep-disordered breathing, particularly in obesity, by enhancing CO2 chemoreflex drive. This offers a pharmacologic alternative or adjunct to CPAP for selected patients pending human trials.
Key Findings
- Setmelanotide increased minute ventilation across sleep/wake states and enhanced the hypercapnic ventilatory response in obese mice.
- Sleep apneas were abolished by setmelanotide treatment.
- Parafacial (but not NTS) MC4R+ neurons mediated the effect; chemogenetic activation augmented HCVR, and caspase ablation eliminated the drug effect.
- Parafacial MC4R+ neurons projected to respiratory premotor neurons at C3–C4.
Methodological Strengths
- Randomized crossover design and repeated dosing paradigms in vivo
- Multimodal mechanistic mapping (in situ mRNA, chemogenetics, targeted ablation and circuit tracing)
Limitations
- Preclinical mouse study; human translatability and dosing/safety remain unknown
- Focused on setmelanotide; class effects and long-term outcomes not assessed
Future Directions: Conduct early-phase clinical trials testing MC4R agonists in obesity-related SDB/OSA, with physiologic endpoints (HCVR, apnea–hypopnea index) and safety; map homologous parafacial circuits in humans.
Weight loss medications are emerging candidates for pharmacotherapy of sleep-disordered breathing (SDB). A melanocortin 4 receptor (MC4R) agonist, setmelanotide (Set), is used to treat obesity caused by abnormal melanocortin and leptin signaling. We hypothesized that Set can treat SDB in mice with diet-induced obesity. We performed a proof-of-concept randomized crossover trial of a single dose of Set versus vehicle and a 2-week daily Set versus vehicle trial, examined colocalization of Mc4r mRNAs with the markers of CO2-sensing neurons Phox2b and neuromedin B in the brainstem, and expressed Cre-dependent designer receptors exclusively activated by designer drugs (DREADDs) or caspase in obese Mc4r-Cre mice. Set increased minute ventilation across sleep/wake states, enhanced the hypercapnic ventilatory response (HCVR), and abolished apneas during sleep. Phox2b+ neurons in the nucleus of the solitary tract (NTS) and the parafacial region expressed Mc4r. Chemogenetic stimulation of the MC4R+ neurons in the parafacial region, but not in the NTS, augmented HCVR without any changes in metabolism. Caspase elimination of the parafacial MC4R+ neurons abolished effects of Set on HCVR. Parafacial MC4R+ neurons projected to the respiratory premotor neurons retrogradely labeled from C3-C4. In conclusion, MC4R agonists enhance the HCVR and treat SDB by acting on the parafacial MC4R+ neurons.
2. Pulmonary outcomes of incretin-based therapies in COPD patients receiving single-inhaler triple therapy.
In matched real-world data of COPD patients with T2DM on single-inhaler triple therapy, GLP-1 receptor agonists were associated with lower risks of COPD exacerbation, pneumonia, oxygen dependence, and all-cause mortality versus DPP4 inhibitors, without excess serious GI events.
Impact: Findings suggest a metabolic therapy could meaningfully improve hard pulmonary outcomes and survival in COPD, supporting integrated care strategies for patients with COPD and T2DM.
Clinical Implications: For COPD patients with T2DM on SITT, GLP-1 receptor agonists may be preferable to DPP4 inhibitors to reduce exacerbations and mortality, warranting consideration in multidisciplinary COPD-diabetes management.
Key Findings
- GLP-1 analogue users had an 18% lower risk of COPD exacerbation (HR 0.82, 95% CI 0.71–0.94).
- Risks of pneumonia (HR 0.72) and oxygen dependence (HR 0.66) were significantly reduced.
- All-cause mortality was 40% lower with GLP-1 analogues (HR 0.60, 95% CI 0.47–0.77).
- No significant increase in serious gastrointestinal adverse events was observed.
Methodological Strengths
- Large multi-institutional EHR cohort with propensity score matching
- Clinically meaningful endpoints (exacerbations, pneumonia, oxygen dependence, mortality)
Limitations
- Observational design with potential residual confounding and confounding by indication
- Limited to COPD patients with T2DM on SITT; generalizability to broader COPD populations uncertain
Future Directions: Prospective trials examining GLP-1RA effects on COPD outcomes irrespective of diabetes status; mechanistic studies on pulmonary anti-inflammatory and infection-modulating pathways.
BACKGROUND: Patients with COPD on triple therapy often face exacerbations and comorbidities. Emerging evidence suggests that glucagon-like peptide-1 (GLP-1) analogues may reduce the risk of exacerbation in patients with COPD and type 2 diabetes mellitus (T2DM). This study investigates the impact of GLP-1 analogues on pulmonary outcomes in patients with COPD on single-inhaler triple therapy (SITT) and T2DM. METHODS: We conducted a retrospective cohort study using the TriNetX database and analysed adult patients with COPD and T2DM who received SITT between April 2005 and July 2023. Patients were categorised into GLP-1 analogue and dipeptidyl peptidase-4 inhibitor (DPP4i) cohorts. The primary efficacy outcome was COPD exacerbation, and the secondary efficacy outcomes were pneumonia, acute respiratory distress syndrome, intubation, oxygen dependence and all-cause mortality. The secondary outcomes were serious gastrointestinal adverse events. RESULTS: We included 6898 patients, with 4184 receiving GLP-1 analogues and 2714 receiving DPP4i. After matching, 1751 GLP-1 analogue users were matched with 1751 DPP4i users. GLP-1 analogue users had an 18% lower risk of COPD exacerbation (hazard ratio (HR) 0.82 (95% CI 0.71-0.94)), a 28% reduced risk of pneumonia (HR 0.72 (95% CI 0.61-0.85)), a 34% reduced risk of oxygen dependence (HR 0.66 (95% CI 0.47-0.91)) and a 40% decreased risk of all-cause mortality (HR 0.60 (95% CI 0.47-0.77)). No significant serious gastrointestinal adverse events were observed. CONCLUSION: GLP-1 analogues may be associated with reduced COPD exacerbations, pulmonary comorbidities and mortality in patients with COPD receiving SITT and T2DM, with no significant serious gastrointestinal safety concerns.
3. Association between glucagon-like peptide-1 receptor agonist use and peri-operative pulmonary aspiration: a systematic review and meta-analysis.
Across 28 observational studies, GLP-1 receptor agonist use did not increase peri-operative pulmonary aspiration, but was associated with markedly higher residual gastric contents despite fasting. Withholding at least one dose before procedures reduced residual gastric content risk.
Impact: This synthesis directly informs global perioperative policies for millions on GLP-1 agents, balancing aspiration risk, fasting protocols, and holding strategies.
Clinical Implications: Use point-of-care gastric ultrasound and risk stratification in GLP-1RA users; consider holding at least one dose pre-procedure when feasible; adapt anesthesia plans (rapid sequence induction, aspiration prophylaxis) recognizing increased residual contents without proven higher aspiration risk.
Key Findings
- No significant association between GLP-1RA use and peri-operative pulmonary aspiration (OR 1.04, 95% CI 0.87–1.25; low certainty).
- Significant increase in residual gastric contents in GLP-1RA users despite fasting (OR 5.96, 95% CI 3.96–8.98).
- Withholding ≥1 dose before procedures associated with lower residual gastric content risk (OR 0.51, 95% CI 0.33–0.81).
Methodological Strengths
- Comprehensive multi-database search with random-effects meta-analyses
- Use of GRADE to rate certainty and separate analyses for aspiration vs residual contents
Limitations
- All included studies observational; outcome definitions and measurement heterogeneity
- Low event rate for aspiration may limit power; overall certainty low to very low
Future Directions: Prospective registries and randomized perioperative management trials (e.g., standardized holding vs continuation) with gastric ultrasound endpoints and clinical aspiration outcomes.
INTRODUCTION: Glucagon-like peptide-1 receptor agonists are known to delay gastric emptying; however, the association between glucagon-like peptide-1 receptor agonist use and peri-operative pulmonary aspiration risk is not known. This systematic review and meta-analysis aimed to summarise the evidence on whether glucagon-like peptide-1 receptor agonist exposure is associated with pulmonary aspiration or increased residual gastric content in fasted patients undergoing procedures requiring anaesthesia or sedation. METHODS: We searched six databases for studies assessing peri-operative pulmonary aspiration or residual gastric contents in fasted patients or volunteers who were using any form of glucagon-like peptide-1 receptor agonist. Pooled odds ratios were estimated for each outcome using random effects meta-analysis. Certainty of evidence for each outcome was assessed using the GRADE framework. RESULTS: Of 9010 screened studies, 28 observational studies were included. In a meta-analysis of nine studies involving 185,414 patients and 471 cases of pulmonary aspiration, glucagon-like peptide-1 receptor agonist exposure was not associated with pulmonary aspiration (OR 1.04, 95%CI 0.87-1.25, low certainty of evidence). In a meta-analysis of 18 studies involving 165,522 patients and 3831 cases of residual gastric contents, glucagon-like peptide-1 receptor agonist exposure was associated with an increased risk of residual gastric contents despite appropriate fasting (odds ratio 5.96, 95%CI 3.96-8.98, low certainty of evidence). In a meta-analysis of five studies involving 1706 patients and 208 cases of residual gastric contents, withholding at least one dose of glucagon-like peptide-1 receptor agonist before a procedure was associated with lower odds of residual gastric contents (odds ratio 0.51, 95%CI 0.33-0.81, very low certainty of evidence). DISCUSSION: Patients using glucagon-like peptide-1 receptor agonists are at increased risk of presenting for anaesthesia with residual gastric contents, though the available evidence does not indicate that this translates to an increased risk of pulmonary aspiration.